​

FibroBiologics Stock (NASDAQ:FBLG)

ForecastOwnershipFinancialsChart
FibroBiologics by TradingView

Previous Close

$0.74

52W Range

$0.70 - $14.40

50D Avg

$0.92

200D Avg

$4.28

Market Cap

$1.49M

Avg Vol (3M)

$212.49K

Beta

1.17

Div Yield

-

FBLG Company Profile

FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

15

IPO Date

Feb 01, 2024

Website

FBLG Performance

FBLG Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-16.65M$-13.74M$-8.89M
Net Income$-18.65M$-11.16M$-16.48M
EBITDA$-16.65M$-10.57M$-15.90M
Basic EPS$-0.42$-0.34$-0.59
Diluted EPS$-0.42$-0.34$-0.59

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
DAREDare Bioscience, Inc.
MBRXMoleculin Biotech, Inc.
ICUSeaStar Medical Holding Corporation
ATHAAthira Pharma, Inc.
ADTXAditxt, Inc.
APLMApollomics, Inc.
LPTXLeap Therapeutics, Inc.
CTXRCitius Pharmaceuticals, Inc.
AIMDAinos, Inc.